During the study, patients received a dose of ibalizumab, which is delivered intravenously, in addition to their failing regimen, for one week.(Shutterstock)

This new HIV therapy could boost immunity levels in patients

By Asian News International | Asian News International, Washington D.c
UPDATED ON AUG 16, 2018 10:59 AM IST
The drug called ibalizumab shall be delivered intravenously every two weeks and lasts longer than current HIV drugs, which are taken daily by mouth.
Story Saved